Some occasional discounts and promotions can substantially reduce the price, which can make their products more accessible for those who might otherwise be priced out
This multi-modal approach makes it uniquely valuable for studying complex neurological conditions where multiple pathways are disrupted, and it crosses the blood-brain barrier via standard injectioneliminating the invasive delivery methods required by individual growth factors
Unlike pharmacological interventions that target single receptors or pathways, GHK-Cus multi-gene modulation touches many of the hallmarks of aging simultaneously: Genomic instability (DNA repair gene upregulation) Epigenetic alterations (chromatin remodeling via altered transcription factor activity) Loss of proteostasis (chaperone and proteasome pathway modulation) Cellular senescence (anti-apoptotic and anti-senescence gene networks) Altered intercellular communication (anti-inflammatory cytokine modulation) This positions GHK-Cu within what researchers increasingly call multi-hallmark peptide therapy a conceptual framework that prioritizes compounds acting across multiple aging mechanisms simultaneously
The researchers observed significant and consistent increases in neuronal activity just minutes following intranasal administration, finding that at least the first peak of activity was linked to epithalons direct action on cortical cells [3]
CAS Number: 863288-34-0 (Modified GRF 1-29 / CJC-1295 no DAC) Molecular Formula: C 152 H 252 N 44 O 42 Molecular Weight: 3367.97 g/mol Synonyms: Modified GRF (129), Mod GRF 1-29, CJC-1295 No DAC Receptor target (in research literature): Growth hormone-releasing hormone (GHRH) receptor Plasma half-life (no DAC): Approximately 30 minutes (vs
But the optimal combination of targets, and the safest way to activate them, remains an active area of research
